ID   MeWo
AC   CVCL_0445
SY   MEWO; Mewo; Me Wo; Me-Wo; Mevo; SK-MEL-MeWo; Mel-MeWo; BI-Mel; EST50
DR   BTO; BTO:0003301
DR   CLO; CLO_0007687
DR   CLO; CLO_0007688
DR   EFO; EFO_0006648
DR   MCCL; MCC:0000341
DR   CLDB; cl3456
DR   CLDB; cl3458
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-65
DR   BCRC; 60540
DR   BCRJ; 0358
DR   BioGRID_ORCS_Cell_line; 184
DR   BioSample; SAMN01821578
DR   BioSample; SAMN01821699
DR   BioSample; SAMN03470821
DR   BioSample; SAMN05292463
DR   BioSample; SAMN10987991
DR   cancercelllines; CVCL_0445
DR   Cell_Model_Passport; SIDM00545
DR   ChEMBL-Cells; CHEMBL3308024
DR   ChEMBL-Targets; CHEMBL613300
DR   CLS; 300285
DR   Cosmic; 721835
DR   Cosmic; 886829
DR   Cosmic; 908128
DR   Cosmic; 928689
DR   Cosmic; 932713
DR   Cosmic; 933141
DR   Cosmic; 972284
DR   Cosmic; 1047647
DR   Cosmic; 1060422
DR   Cosmic; 1132584
DR   Cosmic; 1238113
DR   Cosmic; 1303046
DR   Cosmic; 1995506
DR   Cosmic; 2036702
DR   Cosmic; 2159442
DR   Cosmic; 2163794
DR   Cosmic; 2651875
DR   Cosmic-CLP; 908128
DR   DepMap; ACH-000987
DR   ECACC; 93082609
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   ESTDAB; ESTDAB-050
DR   GDSC; 908128
DR   GEO; GSM156016
DR   GEO; GSM188224
DR   GEO; GSM188254
DR   GEO; GSM188313
DR   GEO; GSM206525
DR   GEO; GSM274688
DR   GEO; GSM827470
DR   GEO; GSM887310
DR   GEO; GSM888386
DR   GEO; GSM1670097
DR   GEO; GSM3039511
DR   GEO; GSM3039514
DR   GEO; GSM3039515
DR   IARC_TP53; 26074
DR   ICLC; HTL97019
DR   JCRB; JCRB0066
DR   LiGeA; CCLE_829
DR   LINCS_LDP; LCL-1253
DR   Lonza; 437
DR   PharmacoDB; Mewo_918_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0445
DR   PubChem_Cell_line; CVCL_0445
DR   Wikidata; Q54905336
RX   DOI=10.1007/978-1-4615-7228-2_39;
RX   DOI=10.1007/BF00199208;
RX   DOI=10.1007/BF00205883;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=978138;
RX   PubMed=1067619;
RX   PubMed=1383272;
RX   PubMed=2068080;
RX   PubMed=3518877;
RX   PubMed=6582512;
RX   PubMed=6935474;
RX   PubMed=6933476;
RX   PubMed=7017212;
RX   PubMed=7175440;
RX   PubMed=7459858;
RX   PubMed=7646526;
RX   PubMed=7908310;
RX   PubMed=9290701;
RX   PubMed=9598804;
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23851445;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=27600516;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://www.synapse.org/#!Synapse:syn31544466
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-532.html
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: ERK genetic alteration cell panel (ATCC TCP-1033).
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Population: Caucasian.
CC   Doubling time: ~32 hours (PBCF).
CC   HLA typing: A*02:01,26:01; B*14:02,38:01; C*08:02,12:03; DPB1*04:01,04:02; DQB1*03:01:01,05:01; DRB1*11:01,01:02 (PubMed=15592718).
CC   HLA typing: A*02:01,26:01 (PubMed=25960936).
CC   HLA typing: A*02:01,26:01; B*14:02,67:02; C*12:03,12:03; DQB1*06:13,06:13; DRB1*11:30,14:17 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Heterozygous (PubMed=9598804).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (PubMed=9598804; PubMed=17260012; PubMed=23851445; ATCC; DepMap).
CC   Sequence variation: Mutation; HGNC; 3688; FGFR1; Simple; p.Pro252Ser (c.754C>T); Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (ATCC).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.39%; Native American=1.31%; East Asian, North=0.6%; East Asian, South=0.77%; South Asian=7.24%; European, North=25.84%; European, South=61.86% (PubMed=30894373).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): ATCC; CLS; Cosmic-CLP; ESTDAB; Genomics_Center_BCF_Technion; JCRB; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12 (ESTDAB)
ST   CSF1PO: 12 (ATCC; CLS; Cosmic-CLP; Genomics_Center_BCF_Technion; JCRB; PubMed=25877200)
ST   D13S317: 8 (Cosmic-CLP; ESTDAB)
ST   D13S317: 8,9 (ATCC; CLS; Genomics_Center_BCF_Technion; JCRB; PubMed=25877200)
ST   D16S539: 10,12
ST   D18S51: 14,17
ST   D21S11: 30,32.2
ST   D3S1358: 17
ST   D5S818: 12,13
ST   D7S820: 10,12
ST   D8S1179: 13,15
ST   FGA: 22
ST   Penta D: 10
ST   Penta E: 5 (CLS)
ST   Penta E: 5,15 (Genomics_Center_BCF_Technion; PubMed=25877200)
ST   TH01: 7,9
ST   TPOX: 8,10 (ATCC; CLS; Cosmic-CLP; Genomics_Center_BCF_Technion; JCRB; PubMed=25877200)
ST   TPOX: 9,11 (ESTDAB)
ST   vWA: 15
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   78Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 44
//
RX   DOI=10.1007/978-1-4615-7228-2_39;
RA   Houghton A.N., Oettgen H.F., Old L.J.;
RT   "Malignant melanoma. Current status of the search for melanoma-specific
RT   antigens.";
RL   (In) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston (1981).
//
RX   DOI=10.1007/BF00199208;
RA   Bruggen J., Sorg C., Macher E.;
RT   "Membrane associated antigens of human malignant melanoma V:
RT   Serological typing of cell lines using antisera from nonhuman
RT   primates.";
RL   Cancer Immunol. Immunother. 5:53-62(1978).
//
RX   DOI=10.1007/BF00205883;
RA   Bruggen J., Macher E., Sorg C.;
RT   "Expression of surface antigens and its relation to parameters of
RT   malignancy in human malignant melanoma.";
RL   Cancer Immunol. Immunother. 10:121-127(1981).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=978138; DOI=10.1084/jem.144.4.873;
RA   Shiku H., Takahashi T., Oettgen H.F., Old L.J.;
RT   "Cell surface antigens of human malignant melanoma. II. Serological
RT   typing with immune adherence assays and definition of two new surface
RT   antigens.";
RL   J. Exp. Med. 144:873-881(1976).
//
RX   PubMed=1067619; DOI=10.1073/pnas.73.9.3278;
RA   Carey T.E., Takahashi T., Resnick-Silverman L.A., Oettgen H.F.,
RA   Old L.J.;
RT   "Cell surface antigens of human malignant melanoma: mixed
RT   hemadsorption assays for humoral immunity to cultured autologous
RT   melanoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976).
//
RX   PubMed=1383272; DOI=10.1172/JCI116007;
RA   Nip J., Shibata H., Loskutoff D.J., Cheresh D.A., Brodt P.;
RT   "Human melanoma cells derived from lymphatic metastases use integrin
RT   alpha v beta 3 to adhere to lymph node vitronectin.";
RL   J. Clin. Invest. 90:1406-1413(1992).
//
RX   PubMed=2068080; DOI=10.1073/pnas.88.14.6028;
RA   Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A.,
RA   Kerbel R.S.;
RT   "Fibroblast cell interactions with human melanoma cells affect tumor
RT   cell growth as a function of tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
//
RX   PubMed=6933476; DOI=10.1073/pnas.77.7.4260;
RA   Houghton A.N., Taormina M.C., Ikeda H., Watanabe T., Oettgen H.F.,
RA   Old L.J.;
RT   "Serological survey of normal humans for natural antibody to cell
RT   surface antigens of melanoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980).
//
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
//
RX   PubMed=7175440; DOI=10.1084/jem.156.6.1755;
RA   Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J.;
RT   "Surface antigens of melanocytes and melanomas. Markers of melanocyte
RT   differentiation and melanoma subsets.";
RL   J. Exp. Med. 156:1755-1766(1982).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=7646526; DOI=10.1006/bbrc.1995.2187;
RA   Artuc M., Nurnberg W., Czarnetzki B.M., Schadendorf D.;
RT   "Characterization of gene regulatory elements for selective gene
RT   expression in human melanoma cells.";
RL   Biochem. Biophys. Res. Commun. 213:699-705(1995).
//
RX   PubMed=7908310; DOI=10.1080/09553009414550371;
RA   Muller W.-U., Bauch T., Streffer C., Niedereichholz F., Bocker W.;
RT   "Comet assay studies of radiation-induced DNA damage and repair in
RT   various tumour cell lines.";
RL   Int. J. Radiat. Biol. 65:315-319(1994).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27600516; DOI=10.1007/s00262-016-1897-3;
RA   Gloger A., Ritz D., Fugmann T., Neri D.;
RT   "Mass spectrometric analysis of the HLA class I peptidome of melanoma
RT   cell lines as a promising tool for the identification of putative
RT   tumor-associated HLA epitopes.";
RL   Cancer Immunol. Immunother. 65:1377-1393(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//